TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30716933
Drug: Low-alcohol orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-alcohol orange beverage (500 mL/day for 2 weeks)
Study: 25784207
Drug: CVC placement
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVC placement in patients with PLT count above 50×10^9/L (group B, 42 patients)
Study: 19395686
Drug: Minimal-contact behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-contact behavioral treatment (n = 392)
Study: 10023791
Drug: Salmeterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (2 puffs: 42 mcg BID)
Study: 10023791
Drug: Albuterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2 puffs, 180 mcg QID)
Study: 10023791
Drug: Salmeterol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (4 puffs: 84 mcg BID)
Study: 10023791
Drug: Albuterol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (4 puffs, 360 mcg BID)
Study: 2829267
Drug: ZK 93,426
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 93,426 (0.04 mg/kg)
Study: 2325251
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3mg in 10ml of saline solution with epinephrine 50 micrograms added
Study: 2325251
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3mg in 10ml of saline solution without epinephrine
Study: 30912701
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g L−1)
Study: 30912701
Drug: Alcohol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.0 g L−1)
Study: 23708322
Drug: Myo-inositol (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (1.1 g) plus D-chiro-inositol (27.6 mg)
Study: 23708322
Drug: D-chiro-inositol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-chiro-inositol (500 mg)
Study: 14985687
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid combined with 0.25 mg vitamin B12 (n=9)
Study: 14985687
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vitamin B6 (n=8)
Study: 14985687
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg vitamin B6 (n=9)
Study: 14985687
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg vitamin B6 (n=8)
Study: 11583721
Drug: Simvastatin 5-10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 5-10 mg/day for 6 months
Study: 9711804
Drug: Intramuscular rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular rabies vaccine (conventional regimen)
Study: 9711804
Drug: Intradermal rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal rabies vaccine (Thai Red Cross schedule)
Study: 9711804
Drug: Intramuscular rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular rabies vaccine with human or equine rabies immune globulin
Study: 9711804
Drug: Intradermal rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal rabies vaccine with human or equine rabies immune globulin
Study: 2646918
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment for intestinal parasite infection
Study: 4916790
Drug: Prednisone (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (20-30 mg/24 hours, average 29 mg/24 hours for at least 6 months, with some receiving it for longer)
Study: 29986146
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ) supplementation (420 mL, 8.4 mmol inorganic nitrate (NO3‐)·day‐1)
Study: 25417708
Drug: MP‐376 (levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP‐376 (levofloxacin inhalation solution)
Study: 23147738
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin (with or without antimicrobial baths)
Study: 21967362
Drug: Intravenous levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levetiracetam (2500 mg) with clonazepam (1 mg)
Study: 21967362
Drug: Clonazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (1 mg) with placebo
Study: 15063564
Drug: Tetravalent acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent acellular pertussis combined vaccine (DTacP-IPV; Tetravac) as second booster
Study: 15063564
Drug: Pentavalent two-component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac)
Study: 9696501
Drug: Lipiodol chemoembolization
Normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol chemoembolization plus tamoxifen (40 mg)
Study: 31804680
Drug: Talc Poudrage
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talc Poudrage (4 g during thoracoscopy under moderate sedation)
Study: 31804680
Drug: Talc Slurry
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talc Slurry (4 g via bedside chest tube with local anesthesia)
Study: 29307999
Drug: dexlansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexlansoprazole 60 mg
Study: 29307999
Drug: esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole 40 mg
Study: 14993087
Drug: Drug and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug and alcohol abuse prevention education
Study: 10977012
Drug: L+G (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: L+G (insulin lispro + glyburide)
Study: 10977012
Drug: NPH+G (bedtime
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH+G (bedtime NPH insulin + glyburide)
Study: 9384424
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 40 mg methylprednisolone with 1% lidocaine
Study: 9384424
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution with 1% lidocaine (control group)
Study: 1586601
Drug: Etretinate 25
Normalized name: etretinate 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate 25 mg orally daily for 6 months
Study: 3543432
Drug: S6472 (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: S6472 (375 mg, 2 times daily for 7 days)
Study: 3543432
Drug: CCL (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCL (250 mg, 3 times daily for 7 days)
Study: 3396471
Drug: Cefotaxime 2g
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime 2g 8‐hourly
Study: 3396471
Drug: Cefoxitin 2g
DrugBank: Cefoxitin (DB01331)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefoxitin 2g 6‐hourly
Study: 3396471
Drug: Clindamycin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (900 mg 8‐hourly) and gentamicin 3 to 5 mg/kg/day in divided doses 8‐hourly
Study: 31985099
Drug: Conventional pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacotherapy (CNT group)
Study: 19438397
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg per day)
Study: 19438397
Drug: Nevirapine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine (400 mg per day)
Study: 17447829
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 3-12 mg/day for 6 weeks
Study: 9669447
Drug: Urapidil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (30 mg)
Study: 30632220
Drug: Valerian root
Normalized name: Valerian Root
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian root extract (VRE) 100 mg thrice daily
Study: 16447240
Drug: High-dose doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose doxycycline (100 mg twice daily) plus methotrexate (MTX)
Study: 16447240
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline (20 mg twice daily) plus methotrexate (MTX)
Study: 11461801
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of investigational drug
Study: 11461801
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of investigational drug
Study: 11461801
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control (e.g., carbamazepine or valproate)
Study: 11461801
Drug: Investigational drug
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug (high dose)
Study: 11461801
Drug: Investigational drug
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug (low dose)
Study: 9490558
Drug: oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral iron therapy alone
Study: 7930915
Drug: Pilocarpine mouthwash
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine mouthwash (5 mg three times a day)
Study: 3555627
Drug: Methylene blue,
Normalized name: Methylene Blue, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue, 15 mg/day
Study: 28760787
Drug: Decision support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision support interventions including patient decision aids for primary endocrine therapy vs surgery/antioestrogen therapy and chemotherapy vs no chemotherapy, and a clinical treatment outcomes algorithm for clinicians.
Study: 23663881
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immunoglobulin (HBIG; three 200 IU intramuscular injections given at four-week intervals starting from gestation week 28)
Study: 23663881
Drug: No HBIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: No HBIG injection
Study: 23663881
Drug: Maternal serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal serum HBV DNA ≥ 10⁷ copies/mL
Study: 23663881
Drug: Maternal serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal serum HBV DNA 10³-10⁶ IU/ml
Study: 23663881
Drug: Maternal serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal serum HBV DNA < 10³ IU/ml
Study: 18679165
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (3.4 +/- 1.1 mL/d)
Study: 2896423
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil
Study: 29723105
Drug: Probiotic administration
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic administration for 4 weeks
Study: 29723105
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration for 4 weeks
Study: 25520127
Drug: 7‐day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐day standard triple therapy plus bismuth and probiotic
Study: 25520127
Drug: 7‐day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐day standard triple therapy with placebo
Study: 25520127
Drug: 14‐day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14‐day standard triple therapy plus bismuth and probiotic
Study: 18698245
Drug: PEG interferon
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG interferon alpha 2b (1.0 microg/kg per week), ribavirin (800 mg/d) plus amantadine (200 mg/d)
Study: 18698245
Drug: PEG interferon
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG interferon alpha 2b (1.0 microg/kg per week) plus ribavirin (800 mg/d)
Study: 15854180
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon alpha-2b combined with lamivudine 100 mg/day
Study: 8740313
Drug: rHuEPO 900
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO 900 U kg‐1 week‐1 with 6 mg kg‐1 day‐1 of iron for 4 weeks
Study: 29342163
Drug: Doxylamine-pyridoxine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxylamine-pyridoxine (10 mg doxylamine and 10 mg pyridoxine, taken 2-4 times per day for 14 days)
Study: 29342163
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablet taken with the same instructions)
Study: 26947173
Drug: Warfarin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (25 mg)
Study: 15657158
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment (6 to 9 million U, 3 times weekly for 26 to 88 weeks)
Study: 2623215
Drug: Nicardipine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine administered intravenously or topically using iontophoresis or occlusive dressing
Study: 28452885
Drug: Metabolic-targeted hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic-targeted hypothermia treatment (MTHT) group, targeting 50% to 60% rest metabolic ratio
Study: 28452885
Drug: Body temperature-targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body temperature-targeted hypothermia treatment (BTHT) group, targeting body temperature of 32°C to 35°C
Study: 18438829
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with methotrexate, sulfasalazine, and prednisone (group 3)
Study: 18438829
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with methotrexate and infliximab (group 4)
Study: 16284067
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg rectally, given as three doses every 12 hours starting the night prior to embryo transfer
Study: 12676418
Drug: Multidimensional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional treatment protocol delivered by nurse practitioners (NP)
Study: 3948474
Drug: Dihydroergotamine (DHE),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE), 0.5 mg im, twice a day from the day of surgery until full mobilization achieved
Study: 26391030
Drug: Multi-modal tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modal tobacco treatment education (MME)
Study: 26391030
Drug: Traditional tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional tobacco treatment education (TE)
Study: 10613168
Drug: Dorsiflexion night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsiflexion night splint for 3 months along with oral antiinflammatory medication, Achilles stretching exercises, and shoe recommendations
Study: 10613168
Drug: Oral antiinflammatory
Normalized name: Arthriten Inflammatory Pain Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiinflammatory medication, Achilles stretching exercises, and shoe recommendations for 1 month
Study: 10613168
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (with and without night splint)
Study: 1773711
Drug: Purified pork
Normalized name: Insulin purified pork
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Purified pork insulin (PPI)
Study: 7002185
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g four times daily for 2 days, then 0.5 g four times daily for the next 2 days
Study: 22139541
Drug: Tongxinluo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo Capsule
Study: 22139541
Drug: Kangxin Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangxin Capsule
Study: 19098197
Drug: 3D sonography
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D sonography with perflubutane contrast agent
Study: 17684211
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 10 mg tablet twice a day during hospitalization
Study: 9205830
Drug: Eprosartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 200 mg orally every 12 h for 4 days
Study: 9205830
Drug: Digoxin 0.6
Normalized name: medigoxin 0.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.6 mg orally alone
Study: 8166054
Drug: Various therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various therapies designed to impact on progression of heart failure
Study: 3308164
Drug: oral cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral cyclical combination of 2 mg estradiol valerate and cyproterone acetate
Study: 3308164
Drug: percutaneous 17
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: percutaneous 17 beta‐estradiol, supplemented by 200 mg oral progesterone during the second year
Study: 22789911
Drug: Telecare device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telecare device kit including monitoring of oxygen saturation, pulse rate, and respiration rate, with medication and purse-lip breathing reminders.
Study: 23438937
Drug: Sertraline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (150 mg daily)
Study: 16160624
Drug: Fluvoxamine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (200 mg daily)
Study: 12749829
Drug: Lipopeptide antibiotics
Normalized name: oligopeptide 104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipopeptide antibiotics
Study: 12749829
Drug: Peptide deformylase
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide deformylase inhibitors
Study: 1928809
Drug: L-dopa 250
Normalized name: L-DOPA 250 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa 250 mg administered orally
Study: 1928809
Drug: Domperidone 20
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 20 mg orally (peripheral DA2 dopamine receptor blocker)
Study: 6137167
Drug: Lormetazepam (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (oral and intravenous)
Study: 30700332
Drug: One-lead handheld
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-lead handheld ECG recordings twice daily and extra recordings in case of palpitations.
Study: 29668467
Drug: Bilateral ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound guided rectus sheath block with 40 ml of 0.25% bupivacaine after induction of general anesthesia (Group II)
Study: 15105384
Drug: Hysteroscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic surgery plus intrauterine application of ACP gel (10 ml)
Study: 9839106
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg/day)
Study: 11437862
Drug: Glibenclamide (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5.0 mg/day)
Study: 1853146
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole once daily
Study: 8020815
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g sucralfate twice daily
Study: 2920066
Drug: GE +
Normalized name: New Image Flange + 1" Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: GE + GU (gemfibrozil + guar gum) 15 g/day
Study: 29206666
Drug: Diclofenac phonophoresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac phonophoresis with combined therapy
Study: 29206666
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) with coupling gel
Study: 16481224
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg alone
Study: 16481224
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg with 2‐h spaced calcium carbonate 500 mg thrice daily
Study: 12795568
Drug: Behavioral family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral family counseling (BFC) plus individual treatment (naltrexone daily in presence of family member)
Study: 12795568
Drug: Individual-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual-based treatment (IBT; naltrexone with no family involvement)
Study: 26856926
Drug: DP-R202 300
Normalized name: DP-303c
DrugBank: DP-303c (DB17212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP-R202 300 mg once daily
Study: 26856926
Drug: Anplag Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anplag Tab 100 mg TID
Study: 25282317
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin therapy (rosuvastatin 40 mg or atorvastatin 80 mg)
Study: 22704854
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine (average end titration dose of 78 mg morphine/d)
Study: 22704854
Drug: Weight-matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-matched placebo capsules
Study: 19449118
Drug: Neoadjuvant LHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant LHRH agonist plus estramustine phosphate (EMP) for 6 months until completion of the 3D-CRT (EMP group, n = 20)
Study: 19449118
Drug: Neoadjuvant LHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant LHRH agonist alone (LHRH group, n = 19)
Study: 17035932
Drug: Spironolactone 300
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 300 mg